Study of XGEVA® (Denosumab) in Chinese Adults and Skeletally Mature Adolescents With Giant Cell Tumor of the Bone

PHASE4Active, not recruitingINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

August 17, 2023

Primary Completion Date

March 7, 2028

Study Completion Date

March 7, 2028

Conditions
Giant Cell Tumor of Bone
Interventions
DRUG

XGEVA®

Participants will receive XGEVA® 120 mg subcutaneously (SC) once every 4 weeks (Q4W) with a loading dose of 120 mg SC on day 8 and day 15.

Trial Locations (10)

10002

National Taiwan University Hospital, Taipei

11217

Taipei Veterans General Hospital, Taipei

100035

Beijing Jishuitan Hospital, Beijing

100044

Peking University Peoples Hospital, Beijing

150000

Harbin Meidical University Cancer Hospital, Harbin

310052

The Second Affiliated hospital of Zhejiang University School of Medicine, Hangzhou

350005

The First Affiliated Hospital of Fujian Medical University, Fuzhou

510630

The Third Affiliated Hospital Of Southern Medical University, Guangzhou

510663

Sun Yat-sen University Cancer Center, Guangzhou

710032

Tangdu Hospital of Air Force Medical University, Xi'an

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Amgen

INDUSTRY